|Bid||0.0000 x 3100|
|Ask||0.0000 x 1100|
|Day's range||0.4101 - 0.4450|
|52-week range||0.3500 - 14.5000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.00|
TC Biopharm (Holdings) ( NASDAQ:TCBP ) Full Year 2022 Results Key Financial Results Revenue: UK£3.84m (up 94% from FY...
EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit. This highly anticipated event, scheduled for April 24-26, 2023 at La Concha Resort in San Juan, Puerto Rico, promises to offer an array of exciting opportunities for funds, compa
A look at the shareholders of TC Biopharm (Holdings) Plc ( NASDAQ:TCBP ) can tell us which group is most powerful. We...